Treatments Compared for Pediatric-Onset Multiple Sclerosis
THURSDAY, Oct. 6, 2022 -- More patients with pediatric-onset multiple sclerosis (POMS) are free of new or newly enlarging (N or NE) T2 hyperintense lesions with dimethyl fumarate (DMF) versus interferonβ-1a (IFNβ-1a) treatment, and the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 6, 2022 Category: Pharmaceuticals Source Type: news
Migraine, Interferon beta-1a and Immunomodulator Therapies Migraine, Interferon beta-1a and Immunomodulator Therapies
In this patient with multiple sclerosis, the addition of interferon beta-1a immunomodulation therapy resolved his severe migraine attacks. Might it be an effective therapy for autoimmune migraine?BMC Anesthesiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 6, 2022 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news
MS drug does NOT improve condition of hospitalized COVID-19 patients and is linked to WORSE outcomes
A clinical trial from the NIH found that there was no difference in the time of recovery when hospitalized Covid patients were given interferon beta-1a compared to just remdesivir. (Source: the Mail online | Health)
Source: the Mail online | Health - October 19, 2021 Category: Consumer Health News Source Type: news
Data up to 8-years for Roche ’s OCREVUS (ocrelizumab) show early and ongoing treatment significantly reduced risk of requiring a walking aid in relapsing multiple sclerosis and disability progression in primary progressive multiple sclerosis
Basel, 13 October 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new long-term data that reinforce the benefit of early initiation and ongoing treatment of OCREVUS® (ocrelizumab) on disability progression in relapsing multiple sclerosis (RMS) and primary progressive MS (PPMS), as well as safety outcomes for an analysis of shorter 2-hour infusion in minority populations. OCREVUS data from all clinical trials consistently show a favourable benefit-risk profile over eight years. Roche and research partners will also present four late-breaking abstracts to share the latest data regarding COVID-19 and vaccine resp...
Source: Roche Investor Update - October 13, 2021 Category: Pharmaceuticals Source Type: news
Data up to 8-years for Roche ’s OCREVUS (ocrelizumab) show early and ongoing treatment significantly reduced risk of requiring a walking aid in relapsing multiple sclerosis and disability progression in primary progressive multiple sclerosis
Basel, 13 October 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new long-term data that reinforce the benefit of early initiation and ongoing treatment of OCREVUS® (ocrelizumab) on disability progression in relapsing multiple sclerosis (RMS) and primary progressive MS (PPMS), as well as safety outcomes for an analysis of shorter 2-hour infusion in minority populations. OCREVUS data from all clinical trials consistently show a favourable benefit-risk profile over eight years. Roche and research partners will also present four late-breaking abstracts to share the latest data regarding COVID-19 and vaccine resp...
Source: Roche Media News - October 13, 2021 Category: Pharmaceuticals Source Type: news
Nebulized Interferon Beta-1a Promising for COVID-19
TUESDAY, Nov. 17, 2020 -- Patients hospitalized with COVID-19 who receive inhaled nebulized interferon beta-1a (SNG001) have greater odds of improvement than those receiving placebo, according to a study published online Nov. 12 in The Lancet... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 17, 2020 Category: Pharmaceuticals Source Type: news
The Lancet Respiratory Medicine: Clinical trial finds inhaled immune response protein increases odds of recovery for hospitalised COVID-19 patients
(The Lancet) Hospitalised COVID-19 patients in the UK who received an inhaled form of interferon beta-1a (SNG001) were more likely to recover and less likely to develop severe symptoms than patients who received a placebo, according to a new clinical trial published inThe Lancet Respiratory Medicine journal. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - November 12, 2020 Category: Infectious Diseases Source Type: news
NIAID Testing Remdesivir Plus MS Drug for COVID-19 NIAID Testing Remdesivir Plus MS Drug for COVID-19
The ACTT-3 randomized controlled trial is testing the safety and efficacy remdesivir in combination with the immunomodulator interferon beta-1a in hospitalized COVID-19 patients.Medscape Medical News (Source: Medscape Emergency Medicine Headlines)
Source: Medscape Emergency Medicine Headlines - August 12, 2020 Category: Emergency Medicine Tags: Neurology & Neurosurgery News Source Type: news
NIH clinical trial testing remdesivir plus interferon beta-1a for COVID-19 treatment begins
The study is anticipated to enroll more than 1,000 hospitalized adults with COVID-19. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - August 6, 2020 Category: American Health Source Type: news
Before a vaccine, we'll need treatments. Is interferon beta-1a a game changer? | Charlotte Summers
It ’s too early to say if the promising therapy can deliver. But it’s a vindication of the UK’s brilliant clinical trial infrastructureCharlotte Summers is a lecturer in intensive care medicine at the University of CambridgeCoronavirus – latest updatesAccording to the current UK government data, there have been nearly 300,000 confirmed cases of Covid-19, and more than45,000 people have died.The scale of this tragedy is therefore huge. And while a vaccine like the onebeing trialled by Oxford University will (hopefully) prevent or lessen the impact of the virus, it will not take away the need for therapies to treat p...
Source: Guardian Unlimited Science - July 21, 2020 Category: Science Authors: Charlotte Summers Tags: Coronavirus outbreak Medical research Science Infectious diseases UK news Source Type: news
New 6-year data for Roche ’s OCREVUS (ocrelizumab) show earlier treatment initiation nearly halves risk of needing walking aid in relapsing multiple sclerosis
Basel, 28 April 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new analyses of Phase III OPERA I and OPERA II studies, as well as the open-label extensions, showing that OCREVUS ® (ocrelizumab) treatment reduced the risk of disease and disability progression in RMS and PPMS. These new analyses add additional evidence to the benefit-risk profile of OCREVUS, including the impact of MS on people’s daily lives. The data were selected for the 72nd American Academy of Neurolog y (AAN) Annual Meeting and will be made available online via virtual presentation in the coming weeks (in lieu of ...
Source: Roche Media News - April 28, 2020 Category: Pharmaceuticals Source Type: news
New 6-year data for Roche ’s OCREVUS (ocrelizumab) show earlier treatment initiation nearly halves risk of needing walking aid in relapsing multiple sclerosis
Basel, 28 April 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new analyses of Phase III OPERA I and OPERA II studies, as well as the open-label extensions, showing that OCREVUS ® (ocrelizumab) treatment reduced the risk of disease and disability progression in RMS and PPMS. These new analyses add additional evidence to the benefit-risk profile of OCREVUS, including the impact of MS on people’s daily lives. The data were selected for the 72nd American Academy of Neurolog y (AAN) Annual Meeting and will be made available online via virtual presentation in the coming weeks (in lieu of ...
Source: Roche Investor Update - April 28, 2020 Category: Pharmaceuticals Source Type: news
UPMC Health Plan reaches deal with pharmaceutical company for MS medications
UPMC Health Plan has reached a deal with a pharmaceutical company that will link reimbursement for two medications for multiple sclerosis to patient outcomes.
Financial terms of the deal between UPMC Health Plan and Biogen (Nasdaq: BIIB) for Tecfidera and Avonex weren't announced. But this value-based agreement, the first of its kind, provides for reimbursement based on how well the drug keeps patients from further disability. Previous contracts have be en tied to health records and claims data.
Yet… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - November 15, 2019 Category: Biotechnology Authors: Paul J. Gough Source Type: news
Company led drug alert: Avonex 30 micrograms/0.5ml solution for injection
Biogen Idec UK is recalling batches of Avonex 30 micrograms/0.5ml solution for injection as a precautionary measure due to a manufacturing issue. (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - October 24, 2019 Category: Drugs & Pharmacology Source Type: news
